Bristol-Myers/Yale R&D agreement
1982 cooperative cancer R&D agreement has been renewed under original terms. Bristol will provide $3 mil. over five-year period for the "development of anticancer antibiotics, studies on overcoming drug resistance of certain cancer cells, identification of drugs that can convert malignant cells to benign cells, synthesis of new anticancer and antiviral drugs, and tests of promising new drugs in patients with cancer," according to Bristol. The company has a licensing option for drugs discovered under the program.
You may also be interested in...
Novavax aims to recruit 10,000 subjects in the UK, and will include a flu vaccination co-administration for some participants.
Accord has launched its first monoclonal antibody biosimilar and fourth biosimilar overall, introducing in the UK the Zercepac version of trastuzumab developed by China’s Shanghai Henlius Biotech.
Alvogen sister company Alvotech is continuing to extend its network of commercial partners by expanding its partnership with DKSH, a Swiss market expansion services group, for the commercialization of six biosimilars in Asian markets.